We've found
8,177
archived clinical trials in
Orthopedic
We've found
8,177
archived clinical trials in
Orthopedic
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
Updated: 12/31/1969
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Skills-Based Program Delivered Via Secure Live Video to Patients With Acute Musculoskeletal Trauma
Updated: 12/31/1969
A Randomized Controlled Trial Testing a Skills-Based Program Called "A Toolkit for Optimal Recovery" Delivered Via Secure Live Video Compared to Standard Medical Care in Patients With Acute Musculoskeletal Injuries
Status: Enrolling
Updated: 12/31/1969
A Skills-Based Program Delivered Via Secure Live Video to Patients With Acute Musculoskeletal Trauma
Updated: 12/31/1969
A Randomized Controlled Trial Testing a Skills-Based Program Called "A Toolkit for Optimal Recovery" Delivered Via Secure Live Video Compared to Standard Medical Care in Patients With Acute Musculoskeletal Injuries
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Database Retrieval for the Comprehensive Shoulder
Updated: 12/31/1969
Comprehensive Shoulder System Database Retrieval
Status: Enrolling
Updated: 12/31/1969
Database Retrieval for the Comprehensive Shoulder
Updated: 12/31/1969
Comprehensive Shoulder System Database Retrieval
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Novel System to Detect Falls in Real-life Conditions
Status: Enrolling
Updated: 12/31/1969
Updated: 12/31/1969
A Novel System to Detect Falls in Real-life Conditions
Status: Enrolling
Updated: 12/31/1969
Updated: 12/31/1969
Click here to add this to my saved trials
Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis
Updated: 12/31/1969
Pre-hospital Advanced Therapies for Control of Hemorrhage (PATCH) - Pelvis
Status: Enrolling
Updated: 12/31/1969
Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis
Updated: 12/31/1969
Pre-hospital Advanced Therapies for Control of Hemorrhage (PATCH) - Pelvis
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Glenohumeral Rotation After Throwing: RCT Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise
Updated: 12/31/1969
Restoration of Glenohumeral Internal Rotation Deficit (GIRD) After Throwing: A Randomized Clinical Trail Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise
Status: Enrolling
Updated: 12/31/1969
Glenohumeral Rotation After Throwing: RCT Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise
Updated: 12/31/1969
Restoration of Glenohumeral Internal Rotation Deficit (GIRD) After Throwing: A Randomized Clinical Trail Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
RCT Determining Best Treatment for Geriatric Acetabular Fractures
Updated: 12/31/1969
Randomized Controlled Trial to Determine the Best Treatment of Acetabular Fractures in Geriatric Patients: Open Reduction Internal Fixation With or Without Primary Total Hip Arthroplasty
Status: Enrolling
Updated: 12/31/1969
RCT Determining Best Treatment for Geriatric Acetabular Fractures
Updated: 12/31/1969
Randomized Controlled Trial to Determine the Best Treatment of Acetabular Fractures in Geriatric Patients: Open Reduction Internal Fixation With or Without Primary Total Hip Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Impact of Different Educational Approaches on Post-operative Opiate Utilization After Elective Lower Extremity Surgery
Updated: 12/31/1969
The Effect of an Educational Pain Approach Before Elective Lower-extremity Surgery on 6-month Post-operative Use of Opioid Medication: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Impact of Different Educational Approaches on Post-operative Opiate Utilization After Elective Lower Extremity Surgery
Updated: 12/31/1969
The Effect of an Educational Pain Approach Before Elective Lower-extremity Surgery on 6-month Post-operative Use of Opioid Medication: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions
Updated: 12/31/1969
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions
Status: Enrolling
Updated: 12/31/1969
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions
Updated: 12/31/1969
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Aquatic vs. Land Locomotor Training Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life
Updated: 12/31/1969
The Efficacy of Aquatic Locomotor Training Compared to Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life
Status: Enrolling
Updated: 12/31/1969
Aquatic vs. Land Locomotor Training Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life
Updated: 12/31/1969
The Efficacy of Aquatic Locomotor Training Compared to Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of SUNPG1622
Updated: 12/31/1969
A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of SUNPG1622
Updated: 12/31/1969
A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
Updated: 12/31/1969
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
Status: Enrolling
Updated: 12/31/1969
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
Updated: 12/31/1969
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Updated: 12/31/1969
Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials